Roth Capital Trims PT on Ligand (LGND) to $138; Will Remove Evomela from Revenue Projections (SPPI)
Tweet Send to a Friend
Roth Capital trimmed its price target on Buy-rated Ligand Pharmaceuticals (Nasdaq: LGND) from $140 to $138 following news that Spectrum ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
